Danuglipron Protocol Guide
Danuglipron is an oral small-molecule GLP-1 receptor agonist developed for weight management and type 2 diabetes research. As an oral formulation, it offers an alternative to injectable GLP-1 therapies. It is being studied in both twice-daily and sustained-release once-daily formulations.
Protocol Overview
- Compound
- Danuglipron (Small-Molecule GLP-1 Agonist for Weight and T2D Research)
- Category
- Oral GLP-1 Receptor Agonist
- Vial Size
- Oral tablet (Per label)
- Reconstitution
- N/A (oral tablet)
- Route
- Oral
- Frequency
- 7 days/week
Administration
Take orally with water. No reconstitution or injection required.
- Take with or without food (unless otherwise noted)
- Store at room temperature in a cool, dry place
- Follow the dosing schedule consistently
Administration Guidelines
- Take orally once or twice daily as directed by protocol
- Dose per product label - follow specific titration schedule provided
- Swallow tablet whole with water
- May be taken with or without food depending on formulation
- If a dose is missed skip it and resume at next scheduled time
- Store tablets at room temperature in original packaging
- Protect from moisture and light
- Document administration times and observations
Storage Requirements
| State | Storage Conditions |
|---|---|
| Sealed container | Room temperature, cool dry place, protect from moisture |
| Opened container | Room temperature, keep sealed, use within 90 days |
Related Tools & Resources
Frequently Asked Questions
See the fact-checked Verified Dosing shown at the top of this page (verified against the FDA label / published trials); always confirm with a licensed provider.
Danuglipron is an oral tablet requiring no reconstitution. Take with or without food as directed per dosing protocol.
Lyophilized (powder): Room temperature, cool dry place, protect from moisture. Reconstituted: Room temperature, keep sealed, use within 90 days.